TwinBeech Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$570K Buy
+752
New +$568K 0.13% 211
2025
Q3
– Sell
-79,286
Closed -$41.6M – 786
2025
Q2
$41.6M Buy
79,286
+26,185
+49% +$14.6M 0.94% 24
2025
Q1
$33.7M Buy
53,101
+27,964
+111% +$19.2M 0.61% 44
2024
Q4
$17.9M Sell
25,137
-20,730
-45% -$17.4M 0.31% 108
2024
Q3
$48.2M Buy
+45,867
New +$51M 0.92% 18
2024
Q2
– Sell
-21,013
Closed -$20.2M – 752
2024
Q1
$20.2M Buy
+21,013
New +$20M 0.42% 68
2023
Q4
– Sell
-248
Closed -$204K – 869
2023
Q3
$204K Sell
248
-20,350
-99% -$16M ﹤0.01% 599
2023
Q2
$14.8M Buy
20,598
+6,922
+51% +$5.34M 0.29% 108
2023
Q1
$11.2M Buy
+13,676
New +$10.3M 0.23% 136
2020
Q1
– Sell
-9,507
Closed -$3.57M – 435
2019
Q4
$3.57M Buy
+9,507
New +$3.2M 1.03% 14

Other funds holding REGN

TwinBeech Capital's REGN Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 752 shares worth $570K. The stake represents 0.13% of the portfolio and ranks #211 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in REGN as recently as Q2 2025.

TwinBeech Capital first reported a position in REGN in Q4 2019 and has held it in 10 quarters since. The position peaked at $48.2M in Q3 2024. 1,427 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • TwinBeech Capital held 752 shares of Regeneron Pharmaceuticals worth $570K as of Q3 2026.
  • Regeneron Pharmaceuticals was a new TwinBeech Capital position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.13% of TwinBeech Capital's portfolio in Q3 2026, its #211 holding.
  • TwinBeech Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 10 quarters since.
  • TwinBeech Capital's Regeneron Pharmaceuticals position peaked at $48.2M in Q3 2024.
  • 1,427 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.